Skip to main content

Table 2 Concentrations (pmol/ml) of the endocannabinoid-type compounds measured in plasma from the non-human primates (n = 3 in each of the two groups) at baseline, during and after treatment with increasing doses of the omega-3 rich phospholipid preparation

From: The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil

Endocannabinoid-type compound

Group

Value

Baseline

Week after start of treatment

2

4

6

8

10

12

14

16

18

20

Anandamide

Control

Mean

4.24

4.80

5.60

4.31

4.82

4.66

6.02

6.19

2.82

5.19

5.15

SEM

2.00

1.18

2.17

0.93

0.80

0.91

3.84

2.65

0.77

1.38

1.67

Treated

Mean

3.07

3.40

2.86

2.98

2.86

3.34

2.28

3.64

4.25

4.05

4.44

SEM

0.52

1.54

0.93

0.56

0.92

1.35

0.97

1.35

1.69

1.53

0.43

2-arachidonoylglycerol

Control

Mean

14.3

21.0

23.1

21.9

27.8

20.7

28.6

22.7

19.0

18.6

22.4

SEM

5.5

13.8

15.9

11.1

19.2

15.2

20.6

12.3

11.8

11.3

15.5

Treated

Mean

16.8

19.2

13.3

9.14

11.7

4.42

8.48

15.0

26.5

16.5

26.4

SEM

6.4

9.2

7.9

1.12

3.3

1.60

4.20

10.0

19.1

9.1

11.3

EPA ethanolamide

Control

Mean

1.36

1.45

0.91

1.25

0.22

0.57

1.00

1.07

2.07

2.04

2.84

SEM

0.49

0.29

0.16

0.31

0.07

0.20

0.07

0.71

0.84

0.62

1.06

Treated

Mean

0.47

1.04

1.05

1.13

0.85

1.00

1.07

0.58

1.34

1.55

0.63

SEM

0.13

0.48

0.34

0.26

0.24

0.17

0.26

0.22

0.93

0.51

0.35

DHA ethanolamide

Control

Mean

1.23

4.67

5.17

6.64

4.95

4.63

4.61

2.28

3.89

5.82

4.80

SEM

0.29

1.35

2.09

1.95

2.45

2.03

2.06

1.10

1.45

2.49

1.91

Treated

Mean

3.06

6.63

8.03

7.24

6.60

7.41

4.96

3.49

5.57

5.97

6.76

SEM

1.68

3.17

2.34

1.52

1.59

1.12

0.89

0.39

1.30

2.83

2.93

Palmitoyl ethanolamide

Control

Mean

54.7

64.7

58.3

94.7

53.5

71.9

89.9

30.8

24.7

59.3

120

SEM

4.70

10.3

15.3

30.5

12.7

11.2

7.80

4.70

1.50

20.8

36.3

Treated

Mean

66.2

62.5

65.6

86.1

58.6

48.4

69.1

78.8

39.5

92.0

120

SEM

19.2

11.9

14.7

17.3

13.9

9.20

2.40

23.7

8.3

31.5

47.9

Oleoyl ethanolamide

Control

Mean

24.2

24.3

19.0

20.3

30.5

28.5

14.0

29.1

17.6

29.3

31.0

SEM

4.44

1.50

2.25

2.23

1.55

2.65

1.35

5.26

4.10

4.60

2.28

Treated

Mean

24.2

22.3

16.0

20.3

24.8

29.9

14.4

36.9

18.0

39.7

45.5

SEM

3.63

6.86

2.05

2.49

6.63

7.76

2.54

15.01

3.03

14.54

9.89

Dose (mg phospholipids/kg bw/day)

50

150

450

0

Dose (mg [EPA/DHA]/kg bw/day)

9.35/5.48

28.0/16.4

84.1/49.3

0/0

  1. Doses of phospholipids and of EPA and DHA are shown at the end of the table